Medical imaging and radiology
Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryElucid PlaqueIQ medical AI product profile
FDA-cleared non-invasive plaque analysis software for coronary CTA workflows that reports plaque composition and vessel-level findings.
Medical imaging and radiology
Best fit
Cardiology and imaging teams evaluating quantitative CCTA plaque analysis for atherosclerosis risk assessment and treatment planning.
- Primary use case
- AI-enabled coronary CTA plaque composition and lesion-level plaque analysis
- Audience
- Cardiology teams, coronary CTA programs, imaging centers, and cardiovascular service lines
- Risk level
- High
- Pricing signal
- Provider and enterprise pricing varies by deployment and reimbursement workflow; verify current terms.
- Official sources
- 5 official sources
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Elucid PlaqueIQ as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Match the PlaqueIQ version, 510(k) record, indication, CCTA acquisition requirements, geography, and reimbursement use before adding it to a clinical pathway. |
|---|---|
| Privacy | Review coronary CTA upload, remote access to PHI, encrypted transfer, retention, support access, subcontractors, customer-controller obligations, and DPF or local transfer terms. |
| Evidence | Assess validation for the target CCTA population, scanner/protocol mix, plaque-composition metrics, lesion-level outputs, reader agreement, and downstream treatment or testing decisions. |
| Workflow | Best governed as physician-reviewed coronary CTA plaque analysis feeding structured cardiology risk assessment, prevention, referral, and follow-up workflows. |
Where Elucid PlaqueIQ fits
Elucid describes PlaqueIQ as FDA-cleared non-invasive plaque analysis based on CCTA and objective histology; FDA materials list PlaqueIQ image-analysis software, while Elucid privacy materials describe PHI handling, remote access, confidentiality, and security controls for medical image processing services.
Not for: Standalone cardiovascular diagnosis, unsupported CTA protocols, or treatment decisions without qualified physician interpretation.
What to verify before using Elucid PlaqueIQ
- FDA 510(k) indication, software version, and whether the intended coronary CTA workflow matches the clearance.
- Image acquisition protocol, CCTA quality requirements, eligible anatomy, and lesion-inspection workflow.
- How PHI and imaging data are transferred, processed, retained, and protected under customer agreements.
- How plaque findings are reviewed, documented, billed, and monitored for downstream testing and treatment impact.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- elucid.com
- elucid.com / elucid-receives-u-s-510k-clearance-of-plaqueiq-image-analysis-software-to-aid-cardiovascular-disease-assessment
- www.accessdata.fda.gov / cdrh_docs / pdf24
- elucid.com / instructions-for-use
- elucid.com / privacy-policy
Related medical AI products
Medical imaging and radiology
Viz.ai
AI-powered care coordination platform with imaging-driven alerts across therapeutic areas.
Medical imaging and radiology
Ferrum Health
Clinical AI governance and deployment platform for health systems adopting multiple imaging or clinical AI models.
Medical imaging and radiology
Blackford Platform
Enterprise medical imaging AI platform for evaluating, deploying, routing, and monitoring multiple radiology AI applications.